Abstract
QSAR analysis was performed using 20 MT1 agonist and 18 MT2 agonist. MODI was 0.6373 in case of MT1 agonist and 0.6299 in case of MT2 agonist. QSAR model for MT1 receptor agonist was pKd = 16.24793(+/- 0.93539) +1.0924(+/-0.18831) ALogP -0.11399(+/-0.01383) apol +0.59876(+/-0.16599) C2SP3 -10.29435(+/-2.81413) E3p and for MT2 receptor agonist was pKd = 6.38692(+/-0.91098) +0.87139(+/-0.20258) ALogP -0.0351(+/-0.00542) AMR +3.33079 (+/-0.80377) SpMin6_Bhm +146.76208(+/-28.14492) VE2_Dt with statistical parameter as Q^2:0.79167, r^2 :0.88878, |r0^2-r'0^2|:0.04633,k:1.03159, [(r^2-r0^2)/r^2]:0.01013, k':0.96695, [(r^2- '0^2)/r^2]:0.06226 and Q^2:0.81401, r^2:0.97384, |r0^2-r'0^2|:0.1039, k:0.98543, [(r^2-r0^2)/r^2]:0.08048, k':1.01351, [(r^2-r'0^2)/r^2]:0.18717 respectively; comply with the Golbraikh and Tropsha acceptable model criteria. The results from MLR Y Randomization test in case of MT1 agonist was cRp^2: 0.7665 and MT2 agonist was cRp^2: 0.7284. Applicability domain were identified by Euclidean and Mahalanobis Distance Method. Finally it was clear that all the predicted data are inside the area of observed data points and also some data are purely overlapped.Dhaka Univ. J. Pharm. Sci. 15(1): 7-19, 2016 (June)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Dhaka University Journal of Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.